Lisa Anson, chief executive of Redx Pharma Plc (LON:REDX), tells Proactive London's Andrew Scott they've received the regulatory green light to re-commence its phase I/II clinical trial of RXC004 on people with solid tumours.
It means the company is on track to restart the study as planned in the first-half.
RXC004 is a new breed of cancer drug called a porcupine inhibitor, with this particular formulation targeting the Wnt signalling pathway, which known to be heavily involved in cell growth and division.
Original Article: Redx Pharma receives approval to re-commence clinical trial of RXC004